Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc.
Plaintiff: Novo Nordisk Inc. and Novo Nordisk A/S
Defendant: Mylan Pharmaceuticals Inc.
Case Number: 1:2024cv00050
Filed: January 12, 2024
Court: US District Court for the District of Delaware
Presiding Judge: Colm F Connolly
Nature of Suit: Patent - Abbreviated New Drug Application(ANDA)
Cause of Action: 35 U.S.C. ยง 271 Patent Infringement
Jury Demanded By: None
Docket Report

This docket was last retrieved on January 29, 2024. A more recent docket listing may be available from PACER.

Date Filed Document Text
January 29, 2024 Filing 8 WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Mylan Pharmaceuticals Inc. waiver sent on 1/26/2024, answer due 3/26/2024. (Murray, Travis)
January 18, 2024 Filing 7 STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf)
January 17, 2024 Remark: MDL panel has been advised. (jfm)
January 17, 2024 Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb)
January 12, 2024 Filing 6 Summons Issued as to Mylan Pharmaceuticals Inc. on 1/12/2024. (jfm)
January 12, 2024 Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc. (jfm)
January 12, 2024 Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,752,198 B2. (jfm)
January 12, 2024 Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/02/2023. Date of Expiration of Patent: 08/24/2038.Thirty Month Stay Deadline: 6/17/2025. (jfm)
January 12, 2024 Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm)
January 12, 2024 Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. (Filing fee $ 405, receipt number ADEDC-4314403.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: #1 Exhibit 1, #2 Civil Cover Sheet)(jfm)

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Delaware District Court's Electronic Court Filings (ECF) System

Search for this case: Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc.
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Web [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Novo Nordisk Inc.
Represented By: Jack B. Blumenfeld
Represented By: Brian P. Egan
Represented By: Travis J Murray
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Novo Nordisk A/S
Represented By: Jack B. Blumenfeld
Represented By: Brian P. Egan
Represented By: Travis J Murray
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Mylan Pharmaceuticals Inc.
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?